TaiGen Biotechnology (太景生技) is a Taiwan-based pharmaceutical company founded in 2001 and headquartered in Taipei, Taiwan, focused on developing novel therapeutics for infectious diseases, central nervous system disorders, and oncology[1]. With a track record of successful drug development and a proprietary small molecule platform, TaiGen has established itself as a leading Taiwan-based pharmaceutical company with expanding global presence[2].
| Attribute | Details |
|---|---|
| Headquarters | Taipei, Taiwan |
| Founded | 2001 |
| Ticker | TPEX: 4157 |
| Focus Areas | Infectious diseases, CNS disorders, oncology |
| Approach | Small molecule drug development, proprietary chemistry platform |
| Website | taigenbiotech.com |
TaiGen's drug discovery platform leverages proprietary medicinal chemistry capabilities[3]:
The company's platform emphasizes:
| Capability | Description |
|---|---|
| Medicinal Chemistry | Proprietary compound libraries and synthesis |
| In vitro Pharmacology | Target engagement and selectivity profiling |
| In vivo Pharmacology | rodent models of disease |
| ADMET | Absorption, metabolism, pharmacokinetics |
TaiGen has been expanding into neurological disorders, recognizing the significant unmet medical need in Parkinson's disease[4]:
Program Rationale:
TaiGen's PD program focuses on several pathological pathways[5]:
| Target | Mechanism | Development Stage |
|---|---|---|
| Neuroprotection | Dopaminergic neuron survival | Research |
| Neuroinflammation | Microglial activation | Research |
| Mitochondrial function | Complex I protection | Research |
| Alpha-synuclein | Aggregation inhibition | Research |
The company's approach includes:
TaiGen has a strong track record in antibiotic development[6]:
The company's oncology portfolio includes[7]:
TaiGen maintains active collaborations with research institutions and pharmaceutical partners[8]:
TaiGen has established clinical development infrastructure:
The global PD market represents significant opportunity[9]:
Taiwan offers unique advantages for drug development:
TaiGen is developing regulatory pathways in:
TaiGen competes with companies in the antibiotic and CNS spaces:
| Company | Focus | Examples |
|---|---|---|
| Merck | Antibiotics, CNS | Antibiotic pipeline |
| GSK | Antibiotics | New antibiotic development |
| Pfizer | CNS | Parkinson's programs |
| TaiGen | Antibiotics, CNS | TG-001, PD program |
TaiGen has been funded through:
TaiGen's development strategy includes[10]:
TaiGen Biotechnology. Company Website. 2026. ↩︎
Taiwan Biotechnology Industry Association. Taiwan Biotech Companies Directory. 2026. ↩︎
Wermuth CG. The practice of medicinal chemistry. J Med Chem. 2016. ↩︎
Kalia LV, et al. Parkinson's disease. Lancet. 2015. ↩︎
Poewe W, et al. Parkinson's disease. Nat Rev Dis Primers. 2017. ↩︎
Silver LL. Novel antibiotics for resistant infections. Curr Opin Pharmacol. 2018. ↩︎
Targeted Oncology. Cancer therapeutics development. Nat Rev Drug Discov. 2019. ↩︎
National Taiwan University. Research Collaboration Programs. 2026. ↩︎
Dorsey ER, et al. Global, regional, and national burden of Parkinson's disease. Lancet Neurol. 2023. ↩︎
DiMasi JA, et al. Trends in R&D investment in the pharmaceutical industry. Nat Rev Drug Discov. 2023. ↩︎